



www.clumberhealth.org

CSHF Board Update



Roe and Gordie Froman's Peach

Board of Directors Grace Wozniak – President Kim Daboo – Vice President Ken Harringer – Treasurer Janice Friis – Secretary Judy Hiller - Recording Secretary Ron Porras - CSCA Liaison Directors: Jennifer L. Amundsen, Carol Page, Jayde Dian

2020 was a significant and transitional year for the CSHF. Shelley Miller decided to resign from the Board in order to make time for other interests and responsibilities. We sincerely thank Shelley for her instrumental service to the CSHF as Treasurer. We appreciate all her efforts and contributions. After thorough deliberation, the Board decided to ask Ken Harringer to fill the vacated Treasurer position on the Board. Ken has taken over the job responsibly and updated many practices to state of the art form. We wanted the CSHF to be a valued International organization, so we contacted Carol Page in the UK and asked her to join our Foundation. To our benefit Carol agreed and she has been an excellent addition with significant contributions to our ideas. Ron Porras joined the Board as the liaison from the CSCA, and he has been a great addition with his computer skills and close contact to the CSCA. Roe Froman DVM decided to resign from the CSHF and focus on the Clumber Spaniel world beyond the CSHF. We cannot thank Roe enough for founding the CSHF in 2007 and working so hard on the Board to support veterinary research designed to benefit Clumber spaniels.

Scientific Advisory Committee

We have a new addition to our Scientific Advisory Committee: Margaret Warner. Margaret joins long term members Larry Schwartz, Ph.D., and Jennifer Rojko, DVM. They have helped the CSHF review and select Grants and research studies to support. We would like to thank Christine Haakenson for her support and advice for many years.

President's Report

2020 was not the year that anyone expected, as a global pandemic changed all of our lives. Instead of our normal routines and activities, we were forced to stay at home for safety and to stop the spread of COVID-19. And while this change often felt limiting, isolating, and very much challenging, there is a certain population that has benefited greatly. Our pets have, most certainly, benefited from all of our increased time spent at home. And we have all have a new appreciation as to what benefits pets can bring in a time of anxiety and uncertainty.

I've always loved my dogs immensely, and I've always known what comfort they provide me when I am feeling low. But, this is my first pandemic (hopefully last), and I didn't realize how much I would appreciate the companionship of my dogs when my emotional needs have changed so drastically. They have been there to be my friend, to be my comedian, to be my trainer, to be my calendar/ alarm clock; especially when I struggle with not being able to have those same interactions with humans. I credit my two Clumbers (Colby and Claude) with ensuring that I am able to still be the person I was before the pandemic. While the day-to-day is different, my positive attitude remains the same, thanks to my Clumbers.

So, that leads to the most important message; dogs provide comfort and joy, and we must do everything we can to ensure that their health remains our main focus. Clumbers are a unique breed, with specific known issues. The CSHF is taking steps to identify the unique issues, as well as more common issues, and support studies that help us identify and support treatment for health issues.

We all love our Clumbers; let's all continue to support additional research, it benefits us all.

Grace Wozniak



Chris and Carol Page's Maya



Patty McIlnay's Eli

CSHF Grant Support

In 2020 the CSHF Supported two Canine Health Foundation Grants at \$3000 each and one Morris Animal Foundation Study for \$5000.

CHF Grant 02669-A: Lipid Composition and Lipid Droplet Dynamics in Canine Pyometra Affected Endometria

Principal Investigator

Ingrid Walter, PhD; University of Veterinary Medicine of Vienna October 1, 2019 - September 30, 2021 **Sponsor(s)**: Clumber Spaniel Health Foundation **Breed(s)**: -All Dogs **Research Program Area**: Reproductive Conditions

ABSTRACT

Pyometra is the most common uterine disease in intact bitches leading to potentially life-threatening complications. Escherichia coli (E.coli) are the most abundant isolated pathogens causing pyometra. Previous studies identified increased amounts of lipid droplets (LDs) in canine endometrial epithelial cells (cEECs) occurring in metestrus, the cyclic stage with the most common presence of pyometra. A specialized receptor relevant for lipid-uptake (SR-B1) to be expressed in cEECs and up-regulated in pyometra affected uteri was also identified. Lipids are attractive targets for pathogens to modulate host cell processes in order to allow pathogenic E. coli infection is assumed. In this study, the lipid composition in the LDs and different members of LD-coating proteins of the cEECs will be investigated in healthy metestrous and pyometra affected uteri. Furthermore, the effects of bacterial infection on lipid composition and LD formation and function will be investigated. Understanding the regulation of lipid metabolism in pyometra etiology has important implications for exploring new therapeutic strategies for management and treatment of this serious uterine disease in intact bitches.



Kim Daboo's Gin and Angus litter



Lisa Chiado and Catherine Cleary's Dapper

CSHF Grant Support (cont.)

CHF Grant 02661: Investigation into Diet-Associated Dilated Cardiomyopathy in Dogs

Grant Status: Open

Grant Amount: \$211,521

Darcy B. Adin, DVM, MS; University of Florida April 1, 2019 - September 30, 2022

Co-investigators: Lisa Freeman, DVM, PhD and John Rush, DVM, MS, Tufts University; Rebecca Stepien, DVM, MS, University of Wisconsin, Madison; Amara Estrada, DVM and Margaret Sleeper, VMD, University of Florida; Joshua Stern, DVM, PhD, University of California, Davis

Sponsor(s): Clumber Spaniel Health Foundation, Golden Retriever Foundation, Gordon Setter Club of America, Inc., National Beagle Club, Portuguese Water Dog Foundation, Inc., Portuguese Water Dog Club of America, Inc., Vizsla Club of America Welfare Foundation, Whippet Health Foundation, Inc.

Breed(s): Whippet, Miniature Schnauzer, Doberman Pinscher, Golden Retriever **Research Program Area**: Cardiology Donate to Support this Research Program Area

ABSTRACT

Dilated cardiomyopathy (DCM) is a serious disease of the heart muscle whereby the heart becomes enlarged with weak contractions. DCM can result in abnormal heart rhythms, congestive heart failure or sudden death. In dogs, DCM most often occurs in large- and giant-breeds, such as Doberman Pinschers, Boxers, Irish Wolfhounds, and Great Danes; in these dogs, survival time after diagnosis is often only months, even with aggressive medical therapy. Recently, veterinary cardiologists have recognized DCM more frequently in all breeds of dogs including mixed breeds, and even those not usually associated with DCM. There is suspicion that the disease in some dogs is associated with boutique, exotic ingredient, or grain-free (BEG) diets. Some affected dogs on such diets have shown reversal or improvement of their disease after changing their diet, supporting a potential association between consumption of a BEG diet and development of DCM. A specific cause, however, has not been identified, despite extensive nutritional testing of the dog foods and the canine patients. Moreover, the extent of the problem is unknown because only dogs that are symptomatic for DCM have been reported. It is possible that more dogs may be affected but not yet showing signs of heart disease. To investigate the extent of diet-associated heart problems in dogs, this multi-institutional team of veterinary cardiologists and nutritionists will prospectively screen a large population of apparently healthy dogs for DCM and compare important cardiac disease measures, including ultrasound of the heart, blood biomarker and taurine concentrations, and the frequency of DCM in dogs eating BEG versus non-BEG diets



Our organization earned a 2021 Gold Seal of Transparency! Now, everyone can view our financial details and learn about the people at our organization.

CSHF Grant Support (cont.)

MAF Grant D19CA-067 – Evaluating a Novel Treatment for a Deadly Blood DisorderCornell University, Robert Goggs, BVSc, PhD, DACVECC, DECVECC, MRCVSProjected Duration: 3 yearsStudy Cost: \$115,720

SUMMARY: Researchers will conduct a clinical trial evaluating a novel treatment for immune-mediated hemolytic anemia, a severe blood disorder in dogs.


DESCRIPTION: Immune-mediated anemia (IMHA) is a serious blood disorder that causes the body to destroy its own red blood cells. Previously funded work identified a safe and promising drug to treat IMHA in dogs. In this study, researchers will further investigate the efficacy of this drug in a clinical trial of client-owned dogs with IMHA. If successful, this would be a major step toward a new drug to treat this deadly disease.



Chris and Carol Page's Sedge



Emily Escalante's Luna



Linda King's Hondo



Cornell University

Robert Goggs BVSc. DACVECC, DECVECC, PhD, MRCVS Assistant Professor, Emergency / Critical Care Department of Clinical Sciences Cornell University Hospital for Animals Ithaca, NY, 14853 <u>rag285@cornell.edu</u> (+1) 607-882-0660

Clumber Spaniel Health Foundation c/o Shelley Miller 6032 Bowater Crossing Hillsborough, NC 27278 USA

April 11th 2020

D19CA-067 Complement inhibition in IMHA: A single-center, double-blinded randomized controlled trial of intravenous C1-INH in dogs with intravascular hemolysis

Dear Ms. Miller

I write to thank the Clumber Spaniel Health Foundation for its generous donation to the Morris Animal Foundation to support our study. Important research projects such as this would not be possible without the support of organizations like yours, and I am very grateful the CSHF has chosen to support our trial.

As you know, immune-mediated hemolytic anemia can be a devastating and fatal disease. In its most severe intravascular form the dog's red blood cells are broken up while still in the bloodstream. This process is caused by activation of the complement protein system and often has life-threatening effects.

We have identified a drug (C1-INH or Ruconest⁽⁸⁾) that can inhibit the activation of the complement protein cascade and the C1INCH trial will evaluating the efficacy of this drug in dogs with intravascular IMHA. If successful, this study will provide clinicians with a new way to treat dogs with this life-threatening disorder and we hope it will help improve outcomes.

We have published our study protocol in the journal *BMC Veterinary Research* and are actively recruiting other centers to participate in the trial in order to complete the study as quickly as possible. I look forward to being able to share the results with you in due course.

Please do not hesitate to contact me should you have any additional questions about the trial.

Yours sincerely,

Robert Goggs

PROGRESS REPORT



Evaluating a Novel Treatment for a Deadly Blood Disorder

Robert Goggs PhD, Cornell University, D19CA-067 Projected End Date: 9/30/22 but may be extended

Immune-mediated hemolytic anemia (IMHA) is a common disease that affects all breeds of dogs and is associated with serious illness and high mortality rates. One form of IMHA, intravascular IMHA, is characterized by the destruction of red blood cells in blood vessels and has a very high mortality rate, despite aggressive treatment. New therapies are desperately needed to improve survival rates in dogs with this form of IMHA.

In a previous Foundation-funded study, researchers at Cornell University analyzed a human medication (C1-INH) they hypothesized might be a viable treatment for intravascular IMHA in dogs. Preliminary findings were promising in dogs. In this grant, the team plans to use C1-INH on clinical cases of intravascular IMHA.

Unfortunately, like many research facilities around the world, the team has been unable to start the trial due to case and personnel restrictions associated with the COVID-19 pandemic. The research team plans to start recruitment of suitable cases once restrictions are lifted. At that time, they have plans in place to identify, screen and enroll patients into the study and to expand enrollment to include patients at other sites.

Findings from this study will be potentially applicable to all breeds of dogs affected by IMHA. In the short-term, the team hopes findings from this study will-provide a novel treatment for dogs with intravascular IMHA. In the long-term, results might help inform the use of complement inhibitors to treat dogs with all forms of IMHA.

Thank you, Clumber Spaniel Health Foundation, for your generous support of this study!

PROGRESS REPORT



Curbing Tumor Growth and Chemotherapy Resistance in Canine Hemangiosarcoma

Erin Dickerson, PhD, University of Minnesota, D17CA-059 Projected End Date: 04/01/21

Morris Animal Foundation-funded researchers at the University of Minnesota are looking at new ways to block hemangiosarcoma tumor growth and cancer spread. They are specifically studying propranolol, a drug commonly used to treat certain forms of heart disease as a promising, new treatment for hemangiosarcoma.

In laboratory studies, the team found that propranolol inhibits key metabolic pathways in hemangiosarcoma cells, preventing tumor cells from dividing and slowing tumor growth. Further studies in mouse models show propranolol alone inhibits tumor growth and works as well as a combination of propranolol with the chemotherapy drug doxorubicin. While doxorubicin alone also slowed growth, propranolol alone or in combination with doxorubicin worked better. The next step is genetic analysis of tumor samples from the different treatment groups (control, doxorubicin, propranolol and propranolol combined with doxorubicin) to better understand the mechanisms used by propranolol to slow or stop tumor growth.

In concurrent studies, the team is studying chemotherapy resistance in hemangiosarcoma cells. So far, they have developed doxorubicin-resistant cell lines and found propranolol sensitizes (increases the effect of) these cell lines to doxorubicin. Further studies are underway to better understand propranolol's effect on drug-resistant cell lines. Identification of changes induced by propranolol in cell lines and tumor samples may provide clues for additional promising treatments combining propranolol with other FDA-approved drugs.

Findings from these studies may help change standard-of-care treatment for canine hemangiosarcoma. Data already is being used to help inform a multi-center clinical trial to determine if propranolol in combination with doxorubicin will improve the overall survival of dogs with hemangiosarcoma compared to doxorubicin alone. If successful, results easily can be translated into a veterinary clinic setting as propranolol is well-tolerated by dogs and can be given orally.

Thank you for your generous support of this study!

720 South Colorado Blvd., Suite 174A, Denver, CO 80246 100 800.243.2345 778 800.243.2345 morrisanimalfoundation.org



RESEARCH PROGRESS REPORT SUMMARY

Grant 02669-A: Lipid Composition and Lipid Droplet Dynamics in Canine Pyometra Affected Endometria

Principal Investigato	r: Ingrid Walter, PhD		
Research Institution	University of Veterinary Medicine of Vie	enna	
Grant Amount:	\$13,608		
Start Date: 10/1/	2019 End Date: 9/30/2021		
Progress Report:	End-Year 1	End-Year 1	
Report Due: 9/30/	Report Received: 9/29/2020		

(The content of this report is not confidential and may be used in communications with your organization.)

Original Project Description:

Pyometra is the most common uterine disease in intact bitches leading to potentially life-threatening complications. *Escherichia coli* (*E.coli*) are the most abundant isolated pathogens causing pyometra. Previous studies identified increased amounts of lipid droplets (LDs) in canine endometrial epithelial cells (cEECs) occurring in metestrus, the cyclic stage with the most common presence of pyometra. A specialized receptor relevant for lipid-uptake (SR-B1) to be expressed in cEECs and up-regulated in pyometra affected uteri was also identified. Lipids are attractive targets for pathogens to modulate host cell processes in order to allow pathogens' survival and replication. A correlation of LD accumulation in cEECs with pyometra-related pathogenic *E. coli* infection is assumed. In this study, the lipid composition in the LDs and different members of LD-coating proteins of the cEECs will be investigated in healthy metestrous and pyometra affected uteri. Furthermore, the effects of bacterial infection on lipid composition and LD formation and function will be investigated. Understanding the regulation of lipid metabolism in pyometra etiology has important implications for exploring new therapeutic strategies for management and treatment of this serious uterine disease in intact bitches.

Publications: None at this time.

Presentations: None at this time.

AKC Canine Health Foundation, Inc. • 8051 Arco Corporate Drive, Suite 300 • Raleigh, NC 27617 • 888-682-9696 • www.akcchf.org

Page 1 of 2



Report to Grant Sponsor from Investigator:

Pyometra is the most common uterine disease in intact bitches leading to potentially life-threatening complications. It is characterized by infection with E. coli bacteria resulting in massive inflammation and accumulation of pus. As pyometra emerges predominantly in metestrus where the surface epithelium of the endometrium is fully packed with lipid droplets, a connection to the disease is assumed. With the present study, we intend to elucidate the nature and role of these lipid droplets as the scientific literature and data available on this topic are very limited. In this project period, we have stained the tissue samples (frozen sections) with oil-red-O to determine the number and distribution of the lipid droplets in the healthy and pyometra-affected canine endometrium. Moreover, a paraphenylenediamine staining that enables the differentiation of triglycerides and phospholipids was applied on single resin embedded tissue samples. This staining indicated the presence of different lipid species in healthy and pyometra samples. Selected endometrial samples were prepared for transmission electron microscopy to determine the size and ultrastructure of lipid droplets, which could help to distinguish different lipid variations. Perilipin immunohistochemistry (PLIN1, PLIN2, PLIN3, PLIN5) was applied to paraffin sections of healthy and pyometra affected tissue. We found apparent differences in PLIN3 expression. We are now in the process to evaluate all staining results in detail. Exogenous lipid sources to cEECs in vitro did not significantly influence replication of the E. coli bacteria. To better understand the lipid metabolism of canine endometrial cells in health and disease we will analyze the expression of a series of genes that are involved in the next step. All these results together should help to find approaches to prevent or treat pyometra in dogs in the future.



We are in the process of preparing a manuscript for submission to the Journal of Veterinary Internal Medicine titled "Effect of Diet Type on Circulating Taurine Concentrations, Cardiac Biomarkers, and Echocardiograms in Four Dog Breeds".

We withdrew the abstract that we had planned to present at the ACVIM Forum because we felt it best to discuss the data only after it had gone through peer review.

Presentations:

None at this time.

Report to Grant Sponsor from Investigator:

The study titled "Investigation into Subclinical Diet-Associated Dilated Cardiomyopathy in Four Dog Breeds" is progressing on schedule. Enrollment for the first part of the study is complete and we are in the midst of statistical analysis of the data in preparation for submission of a publication within the next few months. We are also following dogs enrolled at UF that have bloodwork or echocardiographic abnormalities for a year after a diet change is enacted, to determine if any of the abnormalities will improve with nutritional intervention. We do not know if any or all of these abnormalities in these dogs are related to food and so the role of follow-up is critical to this assessment. The number of dogs being followed at this time is approximately 20% of the total enrolled at UF. We anticipate that this follow-up data will result in a 2nd publication.



We are in the process of preparing a manuscript for submission to the Journal of Veterinary Internal Medicine titled "Effect of Diet Type on Circulating Taurine Concentrations, Cardiac Biomarkers, and Echocardiograms in Four Dog Breeds".

We withdrew the abstract that we had planned to present at the ACVIM Forum because we felt it best to discuss the data only after it had gone through peer review.

Presentations:

None at this time.

Report to Grant Sponsor from Investigator:

The study titled "Investigation into Subclinical Diet-Associated Dilated Cardiomyopathy in Four Dog Breeds" is progressing on schedule. Enrollment for the first part of the study is complete and we are in the midst of statistical analysis of the data in preparation for submission of a publication within the next few months. We are also following dogs enrolled at UF that have bloodwork or echocardiographic abnormalities for a year after a diet change is enacted, to determine if any of the abnormalities will improve with nutritional intervention. We do not know if any or all of these abnormalities in these dogs are related to food and so the role of follow-up is critical to this assessment. The number of dogs being followed at this time is approximately 20% of the total enrolled at UF. We anticipate that this follow-up data will result in a 2nd publication.



Lashnits, E., Neupane, P., Bradley, J. M., Richardson, T., Thomas, R., Linder, K. E., Breen, M., Maggi, R. G., & Breitschwerdt, E. B. (2020). Molecular prevalence of *Bartonella, Babesia*, and hemotropic *Mycoplasma* species in dogs with hemangiosarcoma from across the United States. *PLOS ONE*, 15(1), e0227234. <u>https://doi.org/10.1371/journal.pone.0227234</u>

Maggi RG, Richardson T, Breitschwerdt EB, Miller JC. Development and validation of a droplet digital PCR assay for the detection and quantification of 2 *Bartonella* species within human clinical samples. *J Microbiol Methods.* In Press.

Presentations:

Lashnits E, Abstract oral presentation: Molecular prevalence of *Bartonella, Babesia*, and hemotropic *Mycoplasma* species in dogs with hemangiosarcoma. American College of Veterinary Medicine Annual Forum, Phoenix, AZ, June 12-15, 2018.

Breitschwerdt EB. The genus *Bartonella* and vasoproliferative cancers in dogs and humans. Presented at the 12th Biennial AKC Canine Health Foundation National Parent Club Canine Health Conference in St. Louis, MO August 9-11, 2019.

Report to Grant Sponsor from Investigator:

We are on track to accomplish all of our aims for this study. We were able to obtain the initial set of samples on April 26, 2018 so we had a short delay in starting this study. We have now completed all Year I study aims, with the exception of immunohistochemistry and FISH localization of Bartonella organisms within various cell types. An unanticipated complication arose that the mouse monoclonal antibody was no longer being made commercially. B. henselae specific FISH probes have been designed and validation of FISH probes are in-progress. IHC is also in-progress. All qPCR and ddPCR have been completed at this time and samples are waiting for FISH and IHC analysis. As reported above, we have published a manuscript to the Journal of Clinical Microbiology, representing additional research from our AKC-CHF study #02287, which allowed us to define the Western Blotting (WB) criteria for serodiagnosis of bartonellosis in dogs. That work required additional time and research effort to validate WB testing. We are very excited with the qPCR and ddPCR results obtained from the fresh frozen hemangiosarcoma tissues provided by the NIH-CCOGC. The results strongly support a role for *Bartonella* spp. in the etiopathogenesis of hemangiosarcoma in dogs. The regional study should provide additional insight as to the issue of potential causation. All three of the regions have identified, collected and shipped all necessary samples from their region. These samples have been tested by ddPCR, which has required months of validation. Validation of ddPCR is "In Press" in the Journal of Microbiological Methods. Because of the limitations on research activities at NCSU



Lashnits, E., Neupane, P., Bradley, J. M., Richardson, T., Thomas, R., Linder, K. E., Breen, M., Maggi, R. G., & Breitschwerdt, E. B. (2020). Molecular prevalence of *Bartonella, Babesia*, and hemotropic *Mycoplasma* species in dogs with hemangiosarcoma from across the United States. *PLOS ONE*, 15(1), e0227234. <u>https://doi.org/10.1371/journal.pone.0227234</u>

Maggi RG, Richardson T, Breitschwerdt EB, Miller JC. Development and validation of a droplet digital PCR assay for the detection and quantification of 2 *Bartonella* species within human clinical samples. *J Microbiol Methods*. In Press.

Presentations:

Lashnits E, Abstract oral presentation: Molecular prevalence of *Bartonella, Babesia*, and hemotropic *Mycoplasma* species in dogs with hemangiosarcoma. American College of Veterinary Medicine Annual Forum, Phoenix, AZ, June 12-15, 2018.

Breitschwerdt EB. The genus *Bartonella* and vasoproliferative cancers in dogs and humans. Presented at the 12th Biennial AKC Canine Health Foundation National Parent Club Canine Health Conference in St. Louis, MO August 9-11, 2019.

Report to Grant Sponsor from Investigator:

We are on track to accomplish all of our aims for this study. We were able to obtain the initial set of samples on April 26, 2018 so we had a short delay in starting this study. We have now completed all Year I study aims, with the exception of immunohistochemistry and FISH localization of Bartonella organisms within various cell types. An unanticipated complication arose that the mouse monoclonal antibody was no longer being made commercially. B. henselae specific FISH probes have been designed and validation of FISH probes are in-progress. IHC is also in-progress. All qPCR and ddPCR have been completed at this time and samples are waiting for FISH and IHC analysis. As reported above, we have published a manuscript to the Journal of Clinical Microbiology, representing additional research from our AKC-CHF study #02287, which allowed us to define the Western Blotting (WB) criteria for serodiagnosis of bartonellosis in dogs. That work required additional time and research effort to validate WB testing. We are very excited with the qPCR and ddPCR results obtained from the fresh frozen hemangiosarcoma tissues provided by the NIH-CCOGC. The results strongly support a role for *Bartonella* spp. in the etiopathogenesis of hemangiosarcoma in dogs. The regional study should provide additional insight as to the issue of potential causation. All three of the regions have identified, collected and shipped all necessary samples from their region. These samples have been tested by ddPCR, which has required months of validation. Validation of ddPCR is "In Press" in the Journal of Microbiological Methods. Because of the limitations on research activities at NCSU



during the SARS-CoV2 pandemic, the testing and analysis of the study samples have been delayed. The NCSU College of Veterinary Medicine and the Intracellular Pathogens Research Laboratory have had suspended operations since March 2020. As of July 1, research operations are at limited capacity. Samples will continue to be processed, tested and analyzed as soon as possible given the constraints remaining in place to ensure staff safety. Even though we have had the down time we are still proposing to have this project complete by the end of the study on 1/31/2021.

AKC Canine Health Foundation, Inc. • 8051 Arco Corporate Drive, Suite 300 • Raleigh, NC 27617 • 888-682-9696 • www.akcchf.org

Page 3 of 3

The CSHF has contributed \$3000 to the Theriogenology Residency Program.

The Small Animal Theriogenology Residency Program is a collaboration between the American Kennel Club, the AKC Canine Health Foundation, and the Theriogenology Foundation to increase the number of trained practitioners in companion animal theriogenology and clinical genetics. Theriogenology is the branch of veterinary medicine concerned with reproduction, including the physiology and pathology of male and female reproductive systems, and the clinical practice of veterinary obstetrics, gynecology, and andrology.

Alyssa Helms, DVM (CHF Grant 02390-E) Residency Coordinator: Julie T. Cecere, DVM, DACT, MS; Virginia-Maryland College of Veterinary Medicine

Dr. Helms received her DVM degree, graduating with honors, from The University of Tennessee College of Veterinary Medicine. Her focus on canine reproductive medicine was cultivated throughout her veterinary training through involvement with the local breeder community, canine research and her personal experience owning and exhibiting Australian Shepherds. Dr. Helms is an advocate for the health and preservation of the purpose-bred dogs, and she cares deeply for the breeder community that has supported her work through numerous scholarships, awards, and travel and research grants. Dr. Helms is grateful to the American Kennel Club, the AKC Canine Health Foundation and the Theriogenology Foundation for their support of her specialty training in Theriogenology. She firmly believes that the collaboration of these entities is invaluable in promoting the future health, research and preservation of our beloved dogs.



Alyssa Helms, DVM

TREASURER'S MESSAGE FOR ANNUAL REPORT 2020

It is my honor to introduce myself as the Foundation's new treasurer. Special thanks go out to Shelley Miller, who made the transition a pleasure. Her accurate and sound custody of the Foundation's assets and records, along with her generous sharing of her deep experience, has made coming on board enjoyable.

The Foundation ends the year in fine financial shape, thanks to the generosity of our donors who care so deeply about our breed. We have included our year-end statement of financial activities and balance sheet for your review.

There are ways by which we can extend our generosity and support for Clumber Health. Your employer may provide matching contributions. A company wants to donate to charitable causes, and thru matching programs, they are able to direct their money in ways their employees value. Ask your employer if they provide matching grants. When you shop on Amazon, if you choose "smile.amazon.com," then Amazon will make a contribution to the Foundation equal to 0.5% of your transaction. Same selection, same prices, just with the happy addition of support to our programs. Please use smile for every online purchase!

Thank you very much for your generosity, and for considering the Foundation as a steward for your charitable donations.

Sincerely, Ken Harringer, Treasurer



Ken and Betsy Harringer's Gus



Ken and Betsy Harringer's Percy

Clumber Spaniel Health Foundation, Inc. Balance Sheet

As of December 31, 2020

	Dec 31, 20
ASSETS Current Assets Checking/Savings 10000 · Cash 10010 · Checking 10020 · Savings 10030 · CD 0001 10040 · Paypal	14,343 22,674 4,750 391
Total 10000 · Cash	42,158
Total Checking/Savings	42,158
Other Current Assets 12000 · Undeposited Funds	860
Total Other Current Assets	860
Total Current Assets	43,018
TOTAL ASSETS	43,018
LIABILITIES & EQUITY Equity 31500 · Temp. Restricted Net Assets 31510 · Piper Fund 31520 · Judith Rickey Fund	8,416 2,387
Total 31500 · Temp. Restricted Net Assets	10,804
32000 · Unrestricted Net Assets Net Income	28,514 3,701
Total Equity	43,018
TOTAL LIABILITIES & EQUITY	43,018

Clumber Spaniel Health Foundation, Inc. Statement of Financial Activities

January through December 2020

	Jan - Dec 20
Ordinary Income/Expense Income	
44900 · Restricted Funds released 43400 · Direct Public Support 43410 · Donations - Individual, Busines 43420 · Corporate Contributions & Mat 43430 · Donations - Memoriam Tributes 43498 · Gifts in Kind - Services	361 13,183 7,200 490 227
Total 43400 · Direct Public Support	21,100
44800 · Indirect Public Support 44810 · Affinity Programs	327
Total 44800 · Indirect Public Support	327
45000 · Investments 45030 · Interest-Savings, Short-term CD	1
Total 45000 · Investments	1
Total Income	21,789
Expense 67200 · Program Service Expenses 67210 · Grants 67220 · Testing Subsidy 67230 · Piper Fund Reimbursements	14,000 2,520 361
Total 67200 · Program Service Expenses	16,881
62100 · Contract Services 62150 · Outside Contract Services	291
Total 62100 · Contract Services	291
65000 · Operations 65060 · Bank fees 65030 · Printing and Copying 65040 · Supplies 65050 · Telephone, Telecommunicatio	176 98 54 227
Total 65000 · Operations	556
Total Expense	17,728
Net Ordinary Income	4,062
Other Income/Expense Other Income 70000 · Temporarily Restricted Activity 70200 · Restricted Funds Released	-361
Total 70000 · Temporarily Restricted Ac	-361
Total Other Income	-361
Net Other Income	-361
Net Income	3,701

We would like to thank our donors who make the CSHF's work possible. We offer our sincere gratitude to all of you and thank you for your continued support.

As reported in our 2019 Annual Report, we were saddened during 2020 by the death of longtime supporter, founding board member and former President Wayne Holbrook.

Thank you to those who chose to remember Wayne with donations to the CSHF.

2020 HONOR ROLL

Gold (\$1000 and Over)


Anonymous, Apple Inc*, Kim & Cyrus Daboo, Fannie Mae*, William & Grace Wozniak

Silver (\$500-999)

Janice & Walter Friis


Bronze (\$250-499)

Anonymous, Roe & Gordie Froman, Chip and Shelley Miller



Patty McIlnay's Eli

The Foundation is a tax-exempt public charity under Section 501(c)(3) of the Internal Revenue Code. All donations are tax deductible to the extent allowed by law.



Roe and Gordie Froman's Magic

Partners (\$100-249)

Jennifer Amundsen & Michael Finnegan, Linda Cesal Browder, Lisa Chiado & Ray Palmer, Tamara de Silva, East End Eden Wellness Center, William & Helen Gordon, Mimi Holcombe, Hamby Road Animal Hospital, Ken & Evelyn McWhorter, Linda King, Al & Amy Meadows, Patricia McIlnay, Kathryn O'Connor & Eric Junger, Carrie Pokrefke & BECU Match*, Lizz Squashic, Melanie Steele, Jan & Lorin Sutherland, Merri Van Dyke, Melanie Wilk Thunberg

Friends (\$1-99)

Amazon Smile, Susan Bemis, Michele Marie Blair, Alyson Cleary, Susan & Daniel Cohen, CSCA Members, Jayde Dian, William & Polly Davies, Susan Field, Christine Franey, Pat & Nancy Gardner, Betsy & Ken Harringer, Sharon Harrison, Patricia Holbrook, Benjamin & Karen Hoyle, Collette Jaynes, Steve & Maureen Leland, Kelly Lease, Rose Mahon, Jenney & Tom Marialis, Carol Marvelley, Nancy Merk, Caitlin Ryan, Lisa Schaeffer, Debra & Richard Smith, Jennifer Toebben, Janelle Waldon, John & Naiza Woodlief, Charles Zaragoza

* Employee matching gifts are donations an employer makes to match its employees' charitable contributions. Gifts are typically matched dollar-for-dollar, but some companies will give double or even triple the original donation. Some companies may restrict gifts to categories or charities, but it is worth checking with your HR department to see if your employer matches donations.